Liver Venous Deprivation Versus Portal Vein Embolization Before Major Hepatectomy for Colorectal Liver Metastases: A Retrospective Comparison of Short- and Medium-Term Outcomes

医学 肝切除术 门静脉栓塞 置信区间 回顾性队列研究 栓塞 结直肠癌 外科 胃肠病学 内科学 切除术 癌症
作者
Gianluca Cassese,Roberto Troisi,Salah Khayat,Bachir Benoudifa,François Quénet,Boris Guiu,Fabrizio Panaro
出处
期刊:Journal of Gastrointestinal Surgery [Springer Nature]
卷期号:27 (2): 296-305 被引量:3
标识
DOI:10.1007/s11605-022-05551-2
摘要

Liver venous deprivation (LVD) is a recent radiological technique performed to induce hypertrophy of the future liver remnant. Medium-term results of major hepatectomy after LVD have never been compared with the actual standard of care, portal vein embolization (PVE).We retrospectively compared data from 33 consecutive patients who had undergone LVD (n = 17) or PVE (n = 16) prior to a right hemi-hepatectomy or right extended hepatectomy indicated for colorectal liver metastases (CRLM) between May 2015 and December 2019.The 1-year and 3-year overall survival (OS) rates in the LVD group were 81.3% (95% confidence interval [CI]: 72-90) and 54.7% (95% CI: 46-63), respectively, against 85% (95% CI: 69-101) and 77.4% (95% CI: 54-100) in the PVE group; the differences were not statistically significant (p = 0.64). The median disease-free survival (DFS) rate was also comparable: 6 months (95% CI: 4-7) in the LVD group and 12 months (95% CI: 1.5-13) in the PVE group (p = 0.29). The overall intra-operative and post-operative complication rates were similar between the two groups. The mean daily kinetic growth rate (KGR) was found to be higher after LVD than after PVE (0.2% vs. 0.1%, p = 0.05; 10 cc/day vs. 4.8 cc/day, p = 0.03), as was the mean increase in future liver remnant volume (FLR-V) (49% vs. 27%, p = 0.01).The LVD technique is well tolerated in patients undergoing right hemi-hepatectomy or right extended hepatectomy for CRLM. When compared with the PVE technique, the LVD technique has similar peri-operative and medium-term outcomes, but higher KGR and FLR-V increase.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
诚c发布了新的文献求助10
刚刚
刚刚
饭宝发布了新的文献求助10
1秒前
SciGPT应助大胆的期待采纳,获得10
1秒前
奋斗夏烟完成签到,获得积分20
1秒前
气泡水完成签到 ,获得积分10
1秒前
rosy完成签到,获得积分10
2秒前
rjy完成签到 ,获得积分10
2秒前
3秒前
沙111发布了新的文献求助10
3秒前
MADKAI发布了新的文献求助10
3秒前
4秒前
zhoull完成签到 ,获得积分10
4秒前
4秒前
4秒前
学术蝗虫发布了新的文献求助10
4秒前
aurora完成签到,获得积分10
5秒前
bopbopbaby发布了新的文献求助200
5秒前
sll完成签到,获得积分10
5秒前
犹豫的一斩应助迅速冰岚采纳,获得10
5秒前
聂裕铭完成签到 ,获得积分10
5秒前
谦让成协完成签到,获得积分10
6秒前
6秒前
大个应助侦察兵采纳,获得10
6秒前
科研通AI5应助猪猪hero采纳,获得10
6秒前
6秒前
6秒前
WilsonT完成签到,获得积分10
6秒前
SDS发布了新的文献求助10
7秒前
LLL发布了新的文献求助10
7秒前
爆米花应助娜行采纳,获得10
8秒前
8秒前
虫二队长完成签到,获得积分10
8秒前
8秒前
manan发布了新的文献求助10
8秒前
铸一字错完成签到,获得积分10
8秒前
8秒前
诚c完成签到,获得积分10
8秒前
正在输入中应助niu1采纳,获得10
9秒前
9秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527469
求助须知:如何正确求助?哪些是违规求助? 3107497
关于积分的说明 9285892
捐赠科研通 2805298
什么是DOI,文献DOI怎么找? 1539865
邀请新用户注册赠送积分活动 716714
科研通“疑难数据库(出版商)”最低求助积分说明 709678